Arkolith/Insider Trading/VRNA/Form 4

Hahn Mark W

Chief Financial OfficerVerona Pharma plc (VRNA) · full profile →Form 4 · filed Oct 8, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
3 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 7, 2025Disposed to issuer(D)11.3M——0
Oct 7, 2025Disposed to issuer(D)3.3M——0
Oct 7, 2025Option exercise(M)3.3M——3.3M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 7, 2025Option exercise(M)800K——0
Oct 7, 2025Option exercise(M)390K——0
Oct 7, 2025Option exercise(M)1.6M——0
Oct 7, 2025Grant(A)1.6M——1.6M
Oct 7, 2025Option exercise(M)446K——0

Transaction Codes

D
Disposition to the issuer
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-25-097962) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML